MARKET

PLYX

PLYX

Polaryx Therapeutics, Inc.
NASDAQ
8.91
-7.09
-44.31%
After Hours: 8.35 -0.56 -6.29% 19:52 02/06 EST
OPEN
17.20
PREV CLOSE
16.00
HIGH
17.20
LOW
7.35
VOLUME
188.81K
TURNOVER
--
52 WEEK HIGH
48.91
52 WEEK LOW
7.35
MARKET CAP
421.83M
P/E (TTM)
-40.5000
1D
5D
1M
3M
1Y
5Y
1D
Polaryx Therapeutics, Inc. trading resumes
TipRanks · 1d ago
Polaryx Therapeutics, Inc. trading halted, volatility trading pause
TipRanks · 1d ago
Polaryx appoints Mitchel Berger, Francis Braun, Charles Ryan to board
TipRanks · 2d ago
*Polaryx Therapeutics Names Mitchel Berger, M.D., Francis Braun III, CPA, and Charles Ryan, J.D., Ph.D. to the Board
Dow Jones · 2d ago
*Polaryx Therapeutics: Andrew O Ceased Serving as Member of the Bd Jan 29 >PLYX
Dow Jones · 2d ago
POLARYX THERAPEUTICS WELCOMES NEW MEMBERS OF THE BOARD OF DIRECTORS
Reuters · 2d ago
Polaryx Therapeutics, Inc. trading resumes
TipRanks · 3d ago
Polaryx Therapeutics, Inc. trading halted, volatility trading pause
TipRanks · 3d ago
More
About PLYX
Polaryx Therapeutics, Inc. is a clinical-stage biotech company developing disease-modifying small molecule and gene therapies for rare pediatric lysosomal storage disorders, targeting both genetic causes and downstream pathology. Theirs lead candidate, PLX-200, is advancing toward a Phase 2 basket trial with the potential to become a standard of care across multiple LSDs.

Webull offers Polaryx Therapeutics, Inc. stock information, including NASDAQ: PLYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLYX stock methods without spending real money on the virtual paper trading platform.